Fibrotic Pathways in IPF May Have a Common Protein and New Treatment Target

A motor protein called myosin II was identified in a recent study to be a driver of fibrosis development — a finding with a notable potential to lead to improved treatments for idiopathic pulmonary fibrosis (IPF). The study by  Cleveland Clinic researchers is titled “Matrix-Driven Myosin II Mediates the Pro-Fibrotic Fibroblast Phenotype,“ and was published in the …

  Learn more about pulmonary fibrosis: https://bit.ly/1lfMsiZ…

https://www.youtube.com/watch?v=XmiW-6pOYc0 Sheyenne Lovato talks to you in this video and tells you straight up 10 things you shouldn’t say to someone living with a chronic disease. Learn more about pulmonary fibrosis: https://bit.ly/1lfMsiZ…

In this video share by EdirectTV in 2012, learn more about NHS innovations in health on pulmonary fibrosis treatment. Prof. Roland Du Bois, talks about the challenges related to the management of IPF and “his hopes for the newer approaches emerging to manage the…

A potentially important new study, published in the Journal of Biological Chemistry, identified fibroblast activation protein (FAP) as a crucial factor in collagen fragment clearance in the lungs. Clearing collagen fragments is a key step in reducing tissue scarring and restoring lung function following injury, making FAP an…

https://www.youtube.com/watch?v=NGGyD8i7OxA In 2012, John was diagnosed with idiopathic pulmonary fibrosis (IPF), a condition for which there is no known cure. In this video, John explains how the British Lung Foundation is helping him. Learn more about IPF: https://bit.ly/1QiRmr3…

https://www.youtube.com/watch?v=IXDhKZImx8U Watch this video from Healthy Body, Healthy Mind, to learn more about idiopathic pulmonary fibrosis. Three experts and four patients talk about the disease and their experience with it. Learn more about IPF: https://bit.ly/1QiRmr3…

Boehringer Ingelheim recently announced that OFEV (nintedanib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment for idiopathic pulmonary fibrosis (IPF) within the National Health Service (NHS) in England and in Wales. Nintedanib, an oral small molecule tyrosine kinase inhibitor, is recommended for…

“Marilyn first noticed something was wrong when she kept getting colds and breathing became more difficult. In this video she shares her struggle to get diagnosed with IPF, a condition that causes scarring of the lungs and has no cure.” Learn more about IPF: https://bit.ly/1QiRmr3…

https://www.youtube.com/watch?v=YrdhNG1hbv0 “Lung function of an IPF patient gradually and irreversibly declines.” Learn more about idiopathic pulmonary fibrosis: https://bit.ly/1QiRmr3…